2024 HCPCS Code G9126
Oncology; disease status; chronic myelogenous leukemia, limited to philadelphia chromosome positive and/or bcr-abl positive; in hematologic, cytogenetic, or molecular remission (for use in a medicare-approved demonstration project)
TAGS: philadelphia disease positive chronic demonstration limited molecular chromosome remission myelogenous
Short Description | Onc dx cml remission |
HCPCS Coverage Code | C - Carrier judgment |
HCPCS Action Code | N - No maintenance for this code |
HCPCS Action Effective Date | January 01, 2007 |
HCPCS Code Added Date | January 01, 2006 |
HCPCS Pricing Indicator Code | 00 - Service not separately priced by part B (e.G., services not covered, bundled, used by part a only, etc.) |
HCPCS Multiple Pricing Indicator Code | 9 - Not applicable as HCPCS not priced separately by part B (pricing indicator is 00) or value is not established (pricing indicator is '99') |
HCPCS Coverage Issues Manual Reference Section Number | |
HCPCS Type Of Service Code | 1 - Medical care |
HCPCS Anesthesia Base Unit Quantity | 0 |
Check Similar HCPCS Codes
- G2061 - Qual nonmd est pt 5-10m
- G2062 - Qual nonmd est pt 11-20m
- G2063 - Qual nonmd est pt 21>min
- G2064 - Md mang high risk dx 30
- G2065 - Clin mang h risk dx 30
- G2066 - Inter devc remote 30d
- G2067 - Med assist tx meth wk
- G2068 - Med assist tx bupre oral
- G2069 - Med assist tx inject
- G2070 - Med assist tx implant
- G2071 - Med tx remove implant
- G2072 - Med tx insert/remove imp
- G2073 - Med tx naltrexone
- G2074 - Med assist tx no drug
- G2075 - Med tx meds nos
- G2076 - Intake act w/med exam
- G2077 - Periodic assessment
- G2078 - Take-home meth
- G2079 - Take-hom buprenorphine
- G2080 - Add 30 mins counsel